Skip to main content

Oregon State Flag An official website of the State of Oregon » Homepage

Human Papillomavirus / HPV (vaccine-preventable)

Disease Information

Genital Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI). More than 40 different types are known to exist. Genital HPV is most commonly found in the genital areas of both males and females, but can also infect the mouth and throat. Most people infected with HPV don’t know they have it. However, genital HPV can cause cancer of the cervix and other less common but serious cancers of the vulva, vagina, penis, and anus. A test called a Pap smear can detect the abnormal HPV infections that cause cervical cancer in women. Other types of non-sexually transmitted HPV exist and can cause common warts, often on hands and feet.

Cervical Cancer

Almost all cervical cancers are caused by human papillomavirus (HPV). Most HPV infections resolve on their own, but occasionally, HPV causes pre-cancerous conditions, called Cervical Intraepithelial Neoplasia (CIN) and Adenocarcinoma In Situ (AIS). These, too, often disappear by themselves, but can sometimes turn into cervical cancer after anywhere from 5 to 20 years. Regular Pap smears help doctors and other healthcare practitioners detect the precancerous conditions and treat them, preventing them from becoming cancer.

HPV Vaccine

The HPV vaccines can help prevent cervical cancer. They prevent infection by two HPV subtypes (16 and 18) that cause most cases of cervical cancer. To be most effective, HPV vaccine should be given to young girls and boys beginning at age 9 years, well before they become sexually active. Vaccine can be given to people up to age 24 years, but is not as effective when given after a person has already become sexually active.

Disease Reporting

As of January 1, 2012, all pathology laboratories in Oregon are required to make periodic, direct electronic reports of certain pre-malignant conditions to the Oregon State Cancer Registry (see Oregon Administrative Rule 333-010-0032). These newly reportable conditions include all biopsies indicative of high grade squamous intraepithelial lesions, adenocarcinoma of the uterine cervix, vagina and vulva, and carcinoma in situ of the anus.

Oregon HPV-IMPACT Monitoring Project

About us

Oregon’s Human Papillomavirus (HPV) Vaccine Impact Monitoring Project (HPV-IMPACT) is a project funded by the Centers for Disease Control and Prevention (CDC). The project has been monitoring rates of high-grade cervical lesions in the Metro-Portland area among women aged 18 years and older since 2008.  
Our main objectives are to: 
-  track trends in overall incidence of high-grade cervical lesions (CIN2+) and cervical cancers.
-  better understand the types of women who are getting cervical cancer screenings. 
-  measure the prevalence of cervical cancer genotypes in specimen collections.
-  estimate vaccine effectiveness. 

For Healthcare Providers: Why are we contacting you?

When we have missing data, we will reach out to you for additional information.  We kindly request your help to fill this data gap. A complete HPV vaccine and cervical cancer screening data is crucial to successful HPV surveillance.

We sincerely thank you for being part of this important project. Learn more about the Oregon HPV-IMPACT project on the CDC website.

For more information about HPV, see our HPV-IMPACT’s CD Summary:
If you have any questions, please contact us at

We are located at:

Portland State Office Building
Acute & Communicable Disease Prevention Section
800 NE Oregon Street, Suite 772
Portland, OR 97213

Faxes of Medical Records can go to:  971-673-1100


To help assess the burden of HPV-related problems like cervical cancer and precancerous conditions on Oregonians, the Oregon Public Health Division collects information from laboratories in Oregon about pre-cancerous conditions caused by HPV infection. The mildest type of pre-cancerous condition is CIN 1, followed by CIN 2/3, and CIN 3 and AIS. Laboratories do not report cases of CIN 1, but they do report CIN 2/3, CIN3 and AIS.

Cervical Screening and CIN Rates

Case Counts, 2008 - 2014

HPV Type Distribution, 2008 - 2012

HPV Typing

See Also

CDC Factsheet